产品
编 号：F134649
分子式：C31H38N2O5
分子量：518.64
分子式：C31H38N2O5
分子量：518.64
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1354039-86-3
产品详情
生物活性：
ACT-335827 is a selective, orally active, brain-penetrant orexin type 1 receptor antagonist. ACT-33582 acts on OXR1 and OXR2 with IC50 values of 6 nM and 417 nM, respectively. ACT-33582 can be used in studies related to neurological disorders.
体内研究：
ACT-335827 (oral gavage, 30-100 mg/kg, once) can reduce the fear-induced startle response with no affecting motor or cognitive function in rats.ACT-335827 (oral administration, 300 mg/kg, everyday, 4 weeks) has less effect on metabolic syndrome (MetS), such as diet-induced obesity (DIO) in male Wistar rats.Animal Model:Rats
Dosage:30, 100 or 300 mg/kg
Administration:Oral gavage; once
Result:Reduced fear-induced startle response at 300 mg/kg.Decreased stress-induced elevated body temperature at 300 mg/kg and accelerated heat rate at 100 or 300 mg/kg but no effect on locomotion and blood pressure.
Animal Model:Male Wistar rats weighing160-180g
Dosage:300 mg/kg
Administration:Oral administration; everyday; 4 weeks
Result:Reduced preference for high fat/sweet diets but no effect on absolute energy intake.Increased water intake and HDL relative to total cholesterol.Resulted in a 4% weight gain compared to the control group.
体外研究：
ACT-335827 (0-10 μM, 2 h) acts on OXR-1 and OXR-2 with the Kb values of 41 nM and 560 nM, the IC50 values of 120 nM and 2300 nM, respectively in CHO cells.
ACT-335827 is a selective, orally active, brain-penetrant orexin type 1 receptor antagonist. ACT-33582 acts on OXR1 and OXR2 with IC50 values of 6 nM and 417 nM, respectively. ACT-33582 can be used in studies related to neurological disorders.
体内研究：
ACT-335827 (oral gavage, 30-100 mg/kg, once) can reduce the fear-induced startle response with no affecting motor or cognitive function in rats.ACT-335827 (oral administration, 300 mg/kg, everyday, 4 weeks) has less effect on metabolic syndrome (MetS), such as diet-induced obesity (DIO) in male Wistar rats.Animal Model:Rats
Dosage:30, 100 or 300 mg/kg
Administration:Oral gavage; once
Result:Reduced fear-induced startle response at 300 mg/kg.Decreased stress-induced elevated body temperature at 300 mg/kg and accelerated heat rate at 100 or 300 mg/kg but no effect on locomotion and blood pressure.
Animal Model:Male Wistar rats weighing160-180g
Dosage:300 mg/kg
Administration:Oral administration; everyday; 4 weeks
Result:Reduced preference for high fat/sweet diets but no effect on absolute energy intake.Increased water intake and HDL relative to total cholesterol.Resulted in a 4% weight gain compared to the control group.
体外研究：
ACT-335827 (0-10 μM, 2 h) acts on OXR-1 and OXR-2 with the Kb values of 41 nM and 560 nM, the IC50 values of 120 nM and 2300 nM, respectively in CHO cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备